Phase II study of resection of primary colorectal caner and synchronous liver metastasis after S-1 + oxaliplatin (SOX) + Bevacizumab(Bmab) therapy and adjuvant S-1 chemotherapy - Colorectal cancer with synchronous liver metastasis

Morohashi Hajime0 sites28 target enrollmentStarted: March 25, 2019Last updated: October 17, 2023

Overview

No summary available.

•1\) Hitologically confirmed colon or rectal cancer
•2\) With priary lesion on colon or rectal cancer
•3\) With primary and synchronous liver metastasis without other metastasis
•4\) With evaluable lesion
•5\) Where a surgeon judged hepatectomy is possible. As a measure of initially unresectable liver metastasis, it is assumed that the residual liver volume after hepatectomy is expected to be less than 30% even by portal vein embolism
•6\) Without extrahepatic lesions other than the primary lesion
•1\. Without pulmpnary metastasis by X\-P or CT
•2\. Without hepatic and paraaortic lymph node swelling by CT
•7\) Age of 20\-75 years
•8\) Without prior anti\-tumor therapy (radiation therapy, chemotherapy and hormone therapy)

•1\) with gastrointestinal ulceration or bleeding
•2\) with sensory neuropathy
•3\) with severe diarrhea
•4\) had a previous serious drug allergies
•5\) had pleural effusion or ascites which need therapy
•6\) with brain metastasis or suspected the brain metastases
•7\) had surgery within 28 days before registration
•8\) had thromboembolism, cerebral infarction, pulmonary infarction, interstitial pneumonia
•9\) had serious complication (e.g. interstitialpneumonia, or pulmonary fibrosis, kidney injury, hepatic failure, uncontrolled diabetes mellitus, uncontrolled hypertension)
•10\) with active double cancer

Sponsor

Morohashi Hajime